GIOVANNINI, CATIA
 Distribuzione geografica
Continente #
AS - Asia 4.105
NA - Nord America 3.617
EU - Europa 3.100
AF - Africa 258
SA - Sud America 236
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.323
Nazione #
US - Stati Uniti d'America 3.540
CN - Cina 1.134
IT - Italia 1.084
SG - Singapore 1.040
VN - Vietnam 902
GB - Regno Unito 451
HK - Hong Kong 270
DE - Germania 255
SE - Svezia 243
FR - Francia 185
NL - Olanda 181
IN - India 176
BR - Brasile 170
KR - Corea 157
CH - Svizzera 130
RU - Federazione Russa 98
FI - Finlandia 91
UA - Ucraina 88
IE - Irlanda 86
BD - Bangladesh 85
JP - Giappone 83
ZA - Sudafrica 65
CI - Costa d'Avorio 59
CA - Canada 53
TG - Togo 49
BG - Bulgaria 39
ID - Indonesia 34
SC - Seychelles 33
PH - Filippine 32
JO - Giordania 31
EE - Estonia 30
TH - Thailandia 29
EC - Ecuador 25
PL - Polonia 23
BE - Belgio 21
PK - Pakistan 21
ES - Italia 18
TR - Turchia 18
AR - Argentina 17
MX - Messico 17
AT - Austria 15
NG - Nigeria 14
TW - Taiwan 13
DZ - Algeria 12
SA - Arabia Saudita 11
CZ - Repubblica Ceca 9
IL - Israele 9
IQ - Iraq 9
MK - Macedonia 9
UZ - Uzbekistan 9
HR - Croazia 8
GR - Grecia 7
MY - Malesia 7
RO - Romania 7
TN - Tunisia 7
CO - Colombia 6
LT - Lituania 6
NP - Nepal 6
AU - Australia 5
LB - Libano 5
AM - Armenia 4
ET - Etiopia 4
PE - Perù 4
PY - Paraguay 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
CL - Cile 3
DK - Danimarca 3
EG - Egitto 3
HU - Ungheria 3
IR - Iran 3
KE - Kenya 3
MA - Marocco 3
SK - Slovacchia (Repubblica Slovacca) 3
VE - Venezuela 3
GH - Ghana 2
JM - Giamaica 2
KZ - Kazakistan 2
MD - Moldavia 2
SI - Slovenia 2
SN - Senegal 2
SR - Suriname 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BO - Bolivia 1
BZ - Belize 1
CR - Costa Rica 1
CU - Cuba 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
ML - Mali 1
NO - Norvegia 1
OM - Oman 1
PS - Palestinian Territory 1
Totale 11.318
Città #
Singapore 720
Ashburn 480
Southend 355
Bologna 327
Hefei 321
San Jose 256
Fairfield 247
Hong Kong 247
Chandler 225
Ho Chi Minh City 218
Hanoi 187
Seoul 142
Santa Clara 139
Boardman 130
Houston 120
Bern 119
Wilmington 119
Woodbridge 118
Council Bluffs 111
Beijing 109
Seattle 89
Dublin 86
Milan 83
Princeton 81
Dallas 80
Los Angeles 78
Ann Arbor 77
Helsinki 73
Cambridge 72
Lauterbourg 70
New York 64
Tokyo 64
Abidjan 59
Jacksonville 52
Lomé 49
Florence 41
Da Nang 40
Sofia 38
Dong Ket 37
Turin 36
Nanjing 35
Padova 34
São Paulo 34
Westminster 33
Buffalo 32
Haiphong 32
Amman 31
Bengaluru 30
Johannesburg 30
Amsterdam 29
Chicago 29
Redondo Beach 26
Berlin 25
Munich 25
Jinan 24
Rimini 23
Jakarta 22
Rome 22
Frankfurt am Main 20
London 20
San Diego 19
Montreal 18
Shanghai 18
Changsha 17
Saint Petersburg 17
Guangzhou 16
Hebei 16
Orem 16
Verona 15
Warsaw 15
Brooklyn 14
Brussels 14
Düsseldorf 14
Pune 14
Imola 13
Jiaxing 13
Phoenix 13
Shenyang 13
The Dalles 13
Zhengzhou 13
Can Tho 12
Curitiba 12
Genoa 12
Lahore 12
Abeokuta 11
Bangkok 11
Chennai 11
Medford 11
Mülheim 11
Nuremberg 11
Tongling 11
Edmonton 10
Guayaquil 10
Haikou 10
Hangzhou 10
Hải Dương 10
Modena 10
Norwalk 10
Paris 10
Philadelphia 10
Totale 7.031
Nome #
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 271
Metodo per valutare la capacità di un siero di neutralizzare un virus 262
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 243
Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma 238
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 237
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 233
Fast and real-time electrical transistor assay for quantifying SARS-CoV-2 neutralizing antibodies 232
Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. 231
LncRNAs as novel players in hepatocellular carcinoma recurrence 224
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 222
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 221
Synthetic torpor triggers a regulated mechanism in the rat brain, favoring the reversibility of Tau protein hyperphosphorylation 215
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland 215
Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma (Scientific Reports (2017) 7 (44685) DOI: 10.1038/srep44685) 215
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 203
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 196
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 189
CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. 188
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 187
Organic Electrochemical Transistor (OECT) for Real Time, Electrical quantification of SARS CoV 2 neutralizing antibodies 185
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 184
The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma 184
Determinazione della telomerasi nei tumori mammari della cagna: due metodi a confronto 182
Fibrous hamartoma of corpus cavernosum: a rare cause of congenital penile curvature associated with erectile dysfunction. 181
Neuroendocrine carcinoma of the urinary bladder: case report and review of the literature. 180
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 179
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 178
Molecules Present in Plant Essential Oils for Prevention and Treatment of Colorectal Cancer (CRC) 178
CARCINOMA COMPLETAMENTE NEUROENDOCRINO DELLA VESCICA IN GIOVANE PAZIENTE DI 37 ANNI: CASO CLINICO 177
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 170
Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease 168
GADD45alpha expression in cirrhosis and hepatocellular carcinoma. Relationship with DNA-repair and proliferation. 167
PEDOT:PSS OECTs as versatile devices for real-time monitoring of cytotoxicity and viral infection 166
Pharmaceutical composition and pharmaceutical kit for the treatment oh hepatocellular carcinoma 165
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 161
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 161
Targeting notch3 in hepatocellular carcinoma: Molecular mechanisms and therapeutic perspectives 159
Organic Electrochemical Transistors as Versatile Tool for Real-Time and Automatized Viral Cytopathic Effect Evaluation 158
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 158
Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies 157
Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation. 154
Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC 153
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 153
MicroRNAs in Animal Models of HCC 150
OECTs for in-vitro, real-time impedance monitoring: from single cell sensing to tissue integrity 143
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. 140
Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma. Anticancer Res. 2006 May-Jun;26(3A):1849-54. 139
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 139
Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. 138
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 137
Brivanib in combination with Notch3 silencing shows potent activity in tumour models 136
Characterization of small nucleolar RNA retaining transcripts in human normal and cancer cells 132
T.N.28 P53 IS REGULATED BY NOTCH3 SIGNALLING VIA MDM2 IN HEPATOCELLULAR CARCINOMA 129
p66Shc/Notch-3 interplay controls self renewal and hypoxia survival inhuman stem/progenitor cells of the mammary gland expanded in vitro as mammo-spheres. 126
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 115
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 114
Notch3 intracellular domain accumulates in HepG2 cell line. 110
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 110
Checkpoint effectors CDKN1A and Gadd45 correlate with oxidative DNA damage in human prostate carcinoma. 103
Expression of Fli-1 leads to increased notch activity through overexpression of fringe in colorectal cancer (CRC). 103
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 94
Corrigendum: Synthetic torpor triggers a regulated mechanism in the rat brain, favoring the reversibility of Tau protein hyperphosphorylation (Frontiers in Physiology, (2023), 14, (1129278), 10.3389/fphys.2023.1129278) 91
PEDOT:PSS OECTs as versatile devices for real-time monitoring cytotoxicity and viral infection 89
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 88
PEDOT:PSS OECTs as versatile devices for monitoring cytotoxicity and viral infection in real-time 75
Towards precision medicine: a preliminary collection of patient-derived organoids for the screening of personalised therapies in hepatocellular carcinoma 72
MiR-22-3p targets the G2/M checkpoint inhibitor Wee1 and represents a possible biomarker of TACE response in hepatocellular carcinoma 71
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 70
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 66
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 63
Scaling up in-vitro, real-time cell monitoring through large area printing of PEDOT:PSS OECTs 62
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 59
CXCL3 is a target of miR-30e-3p and predicts tumor escape in sorafenib-treated HCC patients. 58
MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma 51
MiR-30e-3p plays a dual role in hepatocellular carcinoma and predicts tumour escape to sorafenib Treatment 49
Organic Electrochemical Transistors for Real-Time Detection of Immune System Early Activation during Atezolizumab-Bevacizumab Treatment in Hepatocellular Carcinoma 25
Circulating miR-22 Early Predicts TACE Non-Response and Targets WEE1 in Hepatocellular Carcinoma 18
Totale 11.545
Categoria #
all - tutte 31.281
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.281


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021140 0 0 0 0 0 0 0 0 0 0 0 140
2021/2022910 73 35 63 84 69 44 16 79 37 81 211 118
2022/20231.201 111 135 83 132 68 100 22 65 185 29 94 177
2023/2024508 38 61 22 48 31 96 31 46 30 44 26 35
2024/20251.832 86 220 168 105 191 72 140 69 71 181 150 379
2025/20265.237 447 500 425 380 425 274 556 223 1.044 357 295 311
Totale 11.545